TY  - JOUR
AU  - Hoffstetter, Rene
AU  - Riquelme, Ismael
AU  - Andana, Alejandra
AU  - Ili, Carmen G.
AU  - Buchegger, Kurt
AU  - Vargas, Hernán
AU  - Brebi, Priscilla
AU  - Roa, Juan Carlos
PY  - 2017
TI  - Evaluation of DNA methylation in promoter regions of SFRP4 and ZAR1 in urine and plasma of women with cervical lesions
JF  - Translational Cancer Research; Vol 6, No 1 (February 27, 2017): Translational Cancer Research (Focused Issue: Advances on Clinical Immunotherapy)
Y2  - 2017
KW  - 
N2  - Background: Aberrant DNA hypermethylation in tumor suppressor genes is a common feature in cervical cancer (CC). This abnormal hypermethylation could be used as potential biomarkers for detecting CC in non-invasive samples such as urine and plasma.   Methods: This study aimed to evaluate in urine and plasma the methylation status of two genes previously found hypermethylated in CC (ZAR1 and SFRP4) and assesses their diagnostic value. Thus, DNA methylation was measured in 171 paired samples of urine and plasma taken from women with non-lesions [60], low-grade squamous intraepithelial lesions (L-SIL) [40], high-grade squamous intraepithelial lesions (H-SIL) [40] and cervical squamous cell carcinoma (SCC) [31] by quantitative methylation-specific PCR (QMSP).   Results: In urine, a significant difference was observed for methylation levels of SFRP4 between cancer group and all the other groups (P
UR  - https://tcr.amegroups.org/article/view/11960